India is currently charting a unique and sovereign path in **rare disease care** to better serve its vast population. Dr. Rajiv Bahl, Director General of the Indian Council of Medical Research (ICMR), recently emphasized the need for a context-driven approach. Instead of relying solely on Western frameworks, India must focus on resource optimization and indigenous innovation. Consequently, this strategy aims to strengthen the national healthcare response for thousands of affected children.

Rare Disease Care Through Indigenous Innovation

Developing countries often face unique challenges that require local solutions rather than imported models. Dr. Bahl noted that India can leverage its population-based strengths to improve early detection. For instance, the effective use of digital technologies and artificial intelligence can expand outreach significantly. Furthermore, the ICMR is actively promoting the indigenisation of therapies. This effort includes domestic production of affordable alternatives to high-cost drugs. Additionally, six repurposed medications have been identified to improve outcomes and quality of life for patients. Therefore, clinical efforts are now being initiated to integrate these drugs into standard care protocols.

Strengthening the National Policy Framework

Transitioning from the 1990s, the landscape for rare diseases in India has seen remarkable progress. In the past, diagnosis was difficult and treatment was virtually unavailable. However, the National Policy for Rare Diseases 2021 has institutionalized a comprehensive support framework. Union Health Secretary Punya Salila Srivastava highlighted that the number of Centres of Excellence (CoEs) has expanded to fifteen. Financial assistance has also been progressively enhanced to Rs 50 lakh per patient. This funding represents a significant shift in healthcare priorities toward genetic conditions. Moreover, the government is focusing on cost-effective preventive strategies like parental genetic analysis and antenatal diagnosis.

Frontier Technologies and Future Outlook

India is making steady progress in advanced treatments such as gene therapy and CAR-T cell therapy. Collaborative efforts between the ICMR, the Department of Biotechnology, and CSIR are accelerating these breakthroughs. These advancements bring tangible benefits to patients who previously had limited options. Meanwhile, the government continues to seek new ideas to strengthen the management of rare conditions. Sustained commitment from all stakeholders remains essential for a successful national response. Ultimately, this India-specific model provides a source of hope for families across the country.

Frequently Asked Questions

Q1: What is the current financial support for rare disease patients in India?

Under the National Policy for Rare Diseases, patients suffering from identified rare diseases can receive financial assistance of up to Rs 50 lakh for treatment at designated Centres of Excellence.

Q2: How is the ICMR working to make rare disease treatments more affordable?

ICMR is promoting the domestic production of therapies and identifying repurposed drugs that can improve patient quality of life without the extreme costs associated with new orphan drugs.

Q3: What are the preventive strategies mentioned for rare diseases?

The ICMR emphasizes family-based approaches, including parental genetic analysis and antenatal diagnosis, as cost-effective strategies for early intervention and prevention.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. India should chart own path in treatment of rare diseases: ICMR chief - ETHealthworld


2. Ministry of Health and Family Welfare. National Policy for Rare Diseases, 2021.


3. Indian Council of Medical Research (ICMR). Initiatives in Gene Therapy and Rare Disease Management.